Nanomedicine-Driven Precision Therapy for Renal Fibrosis: Bridging Molecular Mechanisms and Targeted Delivery
核心洞察
Chronic kidney disease (搜索) affects over 850 million people globally and is projected to become the 5th leading cause of death by 2040, with renal fibrosis (搜索) serving as the final common pathway to end-stage renal disease.
Current therapies including RAS inhibitors and SGLT2 inhibitors cannot reverse established fibrosis, while biologics targeting TGF-β (搜索) have failed Phase II trials due to compensatory signaling and poor lesion penetration.
Nanomedicine offers a dual-modality approach combining smart drug delivery platforms with intrinsically bioactive nanomaterials to overcome the dense ECM barrier and achieve cell-specific targeting.
Chronic kidney disease (搜索) (CKD) has evolved into a global public health crisis, currently affecting over 850 million individuals worldwide—surpassing 10% of the global population—according to the Global Burden of Disease Study 2021. Predictive models indicate that CKD is on a trajectory to become the 5th leading cause of death globally by 2040. Central to this clinical dilemma is renal fibrosis (搜索), the final common pathway for CKD progression to end-stage renal disease across diverse etiologies, defined by aberrant extracellular matrix (ECM) deposition and disintegration of renal parenchymal architecture.
Despite cornerstone therapies including renin-angiotensin system inhibitors (RASI) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, current treatment strategies face three critical hurdles: the inability to regress established fibrosis, insufficient drug specificity with poor delivery efficiency, and a profound translational gap between mechanistic insights and clinical application. Monoclonal antibodies targeting TGF-β (搜索) or connective tissue growth factor (CTGF (搜索)) have failed to achieve primary efficacy endpoints in Phase II clinical trials, likely owing to activation of compensatory signaling cascades.
The Fibrotic Niche and Cellular Drivers
Renal fibrosis (搜索) is driven by a highly heterogeneous multicellular network. Myofibroblasts (MYFs) function as the principal executioners of aberrant ECM deposition, originating from diverse lineages including resident fibroblasts, pericytes, bone marrow-derived macrophages via macrophage-to-myofibroblast transition (MMT), and endothelial-to-mesenchymal transition (EndoMT). Single-cell transcriptomic analyses have unveiled profound functional heterogeneity, with distinct subpopulations committed to ECM synthesis, migration, or contractile mechanics.
Damaged tubular epithelial cells (TECs) act as active drivers of fibrogenesis through G2/M phase arrest and secretion of pro-inflammatory mediators. Ferroptosis—regulated cell death driven by GPX4 (搜索) inactivation and lipid peroxidation—has emerged as a key pathogenic driver, propagating inflammation via NOX4-induced oxidative stress and TXNIP activation. The TGF-β (搜索)/Smad axis functions as a central regulatory hub, engaging in extensive crosstalk with Wnt/β-catenin and Notch pathways to coordinate ECM production and pericyte transdifferentiation.
Nanomedicine: A Dual-Modality Approach
Nanomedicine offers a transformative solution through two complementary mechanisms: smart drug delivery platforms that achieve specific recognition of renal lesions and effector cells, and nanomaterials with intrinsic therapeutic bioactivity functioning as antioxidant nanozymes or immune microenvironment modulators.
Inorganic nanoparticles have demonstrated particular promise. Cerium oxide nanoparticles (CeO2 NPs), distinguished by reversible Ce3+/Ce4+ valence switching, function as regenerative antioxidants mimicking superoxide dismutase and catalase activities. PEGylated CeO2 NPs were found to reverse the metabolic "Warburg effect" in fibrotic kidneys by inhibiting hexokinase 2 expression and restoring mitochondrial membrane potential. Ultra-small ceria nanoclusters (approximately 1.2 nm) modified with hydrophilic ligands exhibit rapid renal clearance with reduced organ accumulation, effectively suppressing oxidative stress, inflammation, and fibrosis in CKD models.
Gold nanoparticles (AuNPs) have been engineered with folate functionalization to exploit folate receptor overexpression on injured TECs. This triple-action modality—ultra-small size ensuring glomerular filtration, folate ligand facilitating cellular internalization, and the gold core intrinsically inhibiting p38α MAPK phosphorylation—achieved renal accumulation of 3.6% ID/g, significantly outperforming non-targeted counterparts in unilateral ureteral obstruction (UUO) models.
Selenium nanoparticles (SeNPs) function as "nano-Se reservoirs," correcting renal tissue selenium deficiency while upregulating GPx-1 to scavenge ROS and suppressing the NLRP3 inflammasome by blocking caspase-1-mediated maturation of IL-1β/IL-18. In diabetic kidney disease models, chitosan-stabilized SeNPs combined with metformin significantly outperformed monotherapy by downregulating the polyol pathway enzyme aldose reductase and suppressing the TGF-β1 fibrotic axis.
Organic Nanocarriers and Precision Targeting
Lipid nanoparticles (LNPs) constitute the most clinically advanced class of nanomedicines. Biomimetic HDL (bHDL) systems exploit pathological upregulation of KIM-1 to specifically deliver synergistic combinations—such as anti-inflammatory triptolide and anti-fibrotic nintedanib—to injured epithelial cells, effectively inhibiting myofibroblast activation while mitigating systemic toxicity. Sterically stabilized phospholipid nanocarriers (SSLNP) modified with galactosamine target asialoglycoprotein receptors on renal tubules, successfully protecting siRNA targeting CTGF (搜索) from degradation and achieving knockdown in renal tissues.
Chitosan nanoparticles occupy a vanguard position due to their superior biocompatibility, intrinsic mucoadhesion, and pH-responsive swelling behavior enabling triggered drug release within the acidic fibrotic microenvironment. Low-molecular-weight chitosan-miRNA nanocomplexes with optimized dimensions facilitate glomerular filtration while protecting miRNA inhibitors from nuclease degradation. Hyaluronic acid-coated chitosan vectors targeting CD44 receptors have successfully delivered BMP7 and HGF/NK1 plasmids, achieving high renal expression and significant fibrosis reversal.
Overcoming Delivery Barriers
The systemic circulation barrier, glomerular filtration, renal tubular reabsorption and clearance, and ECM deposition represent the main obstacles to effective drug delivery in renal fibrosis (搜索). The glomerular filtration barrier—consisting of endothelial fenestrations (approximately 100 nm), glomerular basement membrane (300 nm thick, 3 nm pore size), and podocyte filtration pores (approximately 32 nm)—restricts most therapeutic nanoparticles of 30–150 nm from entering urine unless they degrade below 10 nm or the glomerular barrier is damaged by disease.
Within the fibrotic niche, the dense, cross-linked ECM forms a formidable physical barrier restricting perfusion and deep penetration of conventional therapeutics. Surface modification of nanoparticles with ECM-degrading enzymes represents one promising approach to enhance penetration and reach target cells.
Future Directions
Current translational efforts face multifaceted challenges including targeting specificity, tissue permeability, carrier stability, biosafety profiles, and manufacturing scalability. The "retention-toxicity" trade-off remains a central concern, particularly for non-biodegradable inorganic nanoparticles where long-term accumulation poses risks. Future engineering must pivot toward biodegradable hybrid architectures and establish rigorous dose-response thresholds. The integration of AI-driven rational design with organoid platforms to decipher structure-activity relationships, combined with the development of intelligent delivery platforms that integrate improved delivery efficiency with therapeutic target regulation and pathological microenvironment remodeling, represents the path toward effective clinical translation.